Catherine Haase (Q138633): Difference between revisions
From geokb
(Created a new Item: Person record added from ORCID registry based on ORCID ID found as author/contributor to USGS publication) |
(Changed an Item: added employer from OpenAlex last known institution and affiliation information) |
||||||||||||||
(4 intermediate revisions by the same user not shown) | |||||||||||||||
Property / instance of: person / reference | |||||||||||||||
Property / ORCID iD | |||||||||||||||
Property / ORCID iD: 0000-0002-7682-0625 / rank | |||||||||||||||
Property / ORCID iD: 0000-0002-7682-0625 / reference | |||||||||||||||
Property / ORCID iD | |||||||||||||||
Property / ORCID iD: 0000-0002-7682-0625 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / ORCID iD: 0000-0002-7682-0625 / qualifier | |||||||||||||||
retrieved: 22 January 2024
| |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Diagnosis and Pathogenesis of Multiple Sclerosis / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Diagnosis and Pathogenesis of Multiple Sclerosis / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Diagnosis and Pathogenesis of Multiple Sclerosis / qualifier | |||||||||||||||
prevalence: 14
| |||||||||||||||
Property / knows about: Diagnosis and Pathogenesis of Multiple Sclerosis / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Role of Microglia in Neurological Disorders / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Role of Microglia in Neurological Disorders / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Role of Microglia in Neurological Disorders / qualifier | |||||||||||||||
prevalence: 6
| |||||||||||||||
Property / knows about: Role of Microglia in Neurological Disorders / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Mammalian MAP Kinase Signaling Pathways / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Mammalian MAP Kinase Signaling Pathways / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Mammalian MAP Kinase Signaling Pathways / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Mammalian MAP Kinase Signaling Pathways / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Guillain-Barré Syndrome and Related Neuropathies / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Guillain-Barré Syndrome and Related Neuropathies / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Guillain-Barré Syndrome and Related Neuropathies / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Guillain-Barré Syndrome and Related Neuropathies / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Innate Immune Recognition and Signaling Pathways / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Innate Immune Recognition and Signaling Pathways / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Innate Immune Recognition and Signaling Pathways / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Innate Immune Recognition and Signaling Pathways / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Structure and Function of Gap Junctions and Connexins / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Structure and Function of Gap Junctions and Connexins / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Structure and Function of Gap Junctions and Connexins / qualifier | |||||||||||||||
prevalence: 4
| |||||||||||||||
Property / knows about: Structure and Function of Gap Junctions and Connexins / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Role of Pim Oncogenes in Tumorigenesis / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Role of Pim Oncogenes in Tumorigenesis / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Role of Pim Oncogenes in Tumorigenesis / qualifier | |||||||||||||||
prevalence: 3
| |||||||||||||||
Property / knows about: Role of Pim Oncogenes in Tumorigenesis / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Advancements in Colorectal Cancer Research / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Advancements in Colorectal Cancer Research / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Advancements in Colorectal Cancer Research / qualifier | |||||||||||||||
prevalence: 3
| |||||||||||||||
Property / knows about: Advancements in Colorectal Cancer Research / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Systemic Lupus Erythematosus and Antiphospholipid Syndrome / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Systemic Lupus Erythematosus and Antiphospholipid Syndrome / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Systemic Lupus Erythematosus and Antiphospholipid Syndrome / qualifier | |||||||||||||||
prevalence: 3
| |||||||||||||||
Property / knows about: Systemic Lupus Erythematosus and Antiphospholipid Syndrome / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Atrial Fibrillation group of topics / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Atrial Fibrillation group of topics / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Atrial Fibrillation group of topics / qualifier | |||||||||||||||
prevalence: 3
| |||||||||||||||
Property / knows about: Atrial Fibrillation group of topics / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Diagnosis and Treatment of Carotid Artery Disease / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Diagnosis and Treatment of Carotid Artery Disease / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Diagnosis and Treatment of Carotid Artery Disease / qualifier | |||||||||||||||
prevalence: 3
| |||||||||||||||
Property / knows about: Diagnosis and Treatment of Carotid Artery Disease / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Chemotherapy-Induced Peripheral Neuropathy in Cancer Treatment / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Chemotherapy-Induced Peripheral Neuropathy in Cancer Treatment / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Chemotherapy-Induced Peripheral Neuropathy in Cancer Treatment / qualifier | |||||||||||||||
prevalence: 3
| |||||||||||||||
Property / knows about: Chemotherapy-Induced Peripheral Neuropathy in Cancer Treatment / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Molecular Mechanisms of Synaptic Plasticity and Neurological Disorders / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Molecular Mechanisms of Synaptic Plasticity and Neurological Disorders / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Molecular Mechanisms of Synaptic Plasticity and Neurological Disorders / qualifier | |||||||||||||||
prevalence: 3
| |||||||||||||||
Property / knows about: Molecular Mechanisms of Synaptic Plasticity and Neurological Disorders / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Blood-Brain Barrier and Neurovascular Interactions / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Blood-Brain Barrier and Neurovascular Interactions / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Blood-Brain Barrier and Neurovascular Interactions / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: Blood-Brain Barrier and Neurovascular Interactions / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Pathology and Management of Trigeminal Neuralgia / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Pathology and Management of Trigeminal Neuralgia / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Pathology and Management of Trigeminal Neuralgia / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: Pathology and Management of Trigeminal Neuralgia / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: mTOR Signaling in Growth and Disease / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: mTOR Signaling in Growth and Disease / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: mTOR Signaling in Growth and Disease / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: mTOR Signaling in Growth and Disease / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Structure and Function of Nicotinic Receptors / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Structure and Function of Nicotinic Receptors / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Structure and Function of Nicotinic Receptors / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: Structure and Function of Nicotinic Receptors / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Diagnosis and Management of Cerebral Vein Thrombosis / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Diagnosis and Management of Cerebral Vein Thrombosis / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Diagnosis and Management of Cerebral Vein Thrombosis / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: Diagnosis and Management of Cerebral Vein Thrombosis / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Adult Neurogenesis and Brain Development / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Adult Neurogenesis and Brain Development / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Adult Neurogenesis and Brain Development / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: Adult Neurogenesis and Brain Development / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Epidemiology and Pathogenesis of Bacterial Meningitis / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Epidemiology and Pathogenesis of Bacterial Meningitis / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Epidemiology and Pathogenesis of Bacterial Meningitis / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: Epidemiology and Pathogenesis of Bacterial Meningitis / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Brain Fluid Dynamics and Waste Clearance Mechanisms / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Brain Fluid Dynamics and Waste Clearance Mechanisms / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Brain Fluid Dynamics and Waste Clearance Mechanisms / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: Brain Fluid Dynamics and Waste Clearance Mechanisms / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Peroxisome Proliferator-Activated Receptors / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Peroxisome Proliferator-Activated Receptors / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Peroxisome Proliferator-Activated Receptors / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: Peroxisome Proliferator-Activated Receptors / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Ocular Manifestations of COVID-19 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Ocular Manifestations of COVID-19 / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Ocular Manifestations of COVID-19 / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: Ocular Manifestations of COVID-19 / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Mammalian Circadian Rhythms and Physiology / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Mammalian Circadian Rhythms and Physiology / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Mammalian Circadian Rhythms and Physiology / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: Mammalian Circadian Rhythms and Physiology / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Epidemiology and Management of Stroke / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Epidemiology and Management of Stroke / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / knows about: Epidemiology and Management of Stroke / qualifier | |||||||||||||||
prevalence: 2
| |||||||||||||||
Property / knows about: Epidemiology and Management of Stroke / reference | |||||||||||||||
Property / OpenAlex ID | |||||||||||||||
Property / OpenAlex ID: A5008490707 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / OpenAlex ID: A5008490707 / qualifier | |||||||||||||||
last update: 23 August 2024
| |||||||||||||||
Property / OpenAlex ID: A5008490707 / qualifier | |||||||||||||||
retrieved: 29 August 2024
| |||||||||||||||
Property / employer | |||||||||||||||
Property / employer: The University of Texas Health Science Center at Houston / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / employer: The University of Texas Health Science Center at Houston / qualifier | |||||||||||||||
point in time: 2024
| |||||||||||||||
Property / employer: The University of Texas Health Science Center at Houston / reference | |||||||||||||||
Revision as of 19:48, 9 September 2024
a record for a person added from ORCID based on a contributor to a USGS publication
Language | Label | Description | Also known as |
---|---|---|---|
English | Catherine Haase |
a record for a person added from ORCID based on a contributor to a USGS publication |
Statements
23 August 2024
14
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference
23 August 2024
1 reference